Stuart A. Arbuckle
2020
In 2020, Stuart A. Arbuckle earned a total compensation of $7.3M as EVP & Chief Operating Officer at Vertex Pharmaceuticals, a 6% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,159,200 |
|---|---|
| Salary | $830,769 |
| Stock Awards | $5,250,411 |
| Other | $42,598 |
| Total | $7,282,978 |
Arbuckle received $5.3M in stock awards, accounting for 72% of the total pay in 2020.
Arbuckle also received $1.2M in non-equity incentive plan, $830.8K in salary and $42.6K in other compensation.
Rankings
In 2020, Stuart A. Arbuckle's compensation ranked 1,323rd out of 13,090 executives tracked by ExecPay. In other words, Arbuckle earned more than 89.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,323 out of 13,090 | 90th |
Division Manufacturing | 476 out of 5,621 | 92nd |
Major group Chemicals And Allied Products | 167 out of 2,254 | 93rd |
Industry group Drugs | 143 out of 1,954 | 93rd |
Industry Pharmaceutical Preparations | 104 out of 1,459 | 93rd |
Source: SEC filing on April 7, 2022.
Arbuckle's colleagues
We found three more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2020.